Tag Archive for: data

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Data demonstrate that uPARAP is highly expressed in tumor samples obtained from glioblastoma multiforme patients uPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumor activity in a glioblastoma multiforme PDX model Data provides evidence that uPARAP targeting ADCs are a potential novel treatment option for glioblastoma multiforme […]

STORM Therapeutics to Present Data on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at AACR Annual Meeting 2024

Late breaking presentation on STORM’s METTL1 inhibitors, for the treatment of cancer, on 8 April 2024 26 March 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig, Group Leader at STORM, […]

Poolbeg Pharma plc – Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

Market opportunity estimated to be greater than US$1 billion Key highlights –      Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model –      Data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS –      Independent Advisory Board supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced […]

Poolbeg Pharma – POLB 001 Data Presented at ASH

11 December 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need and with a lack of treatment alternatives, announces key insights from its poster presentation at the prestigious, 65th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, San Diego.  Read […]

Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO Immuno-Oncology Congress 2023

Updated safety and clinical efficacy data presented at leading immuno-oncology conference Exploratory studies suggest roginolisib boosts antitumoral immunity, whilst simultaneously disrupting tumor survival mechanisms Data suggest the potential of radiomics to assess changes in lesions over time, adding value above RECIST (Response Evaluation Criteria in Solid Tumors) Geneva, Switzerland and Amsterdam, The Netherlands, 8 December […]